PCSK9 inhibitors in clinical practice: Novel directions and new experiences

Volume: 61, Issue: 4, Pages: 241 - 245
Published: Jul 1, 2020
Abstract
Background null In randomized clinical trials, proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) effectively reduce low-density lipoprotein-cholesterol (LDL-C) with a favorable tolerability and safety profile. Our purpose is to provide real-world data regarding the indications, efficacy and safety of PCSK9i. null null null Methods null The cohort comprised 141 patients who attended the lipid clinic of 3 hospitals in Greece and...
Paper Details
Title
PCSK9 inhibitors in clinical practice: Novel directions and new experiences
Published Date
Jul 1, 2020
Volume
61
Issue
4
Pages
241 - 245
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.